We study the impact of product margins on pharmacies’ incentive to promote generics instead of brand-names. First, we construct a theoretical model where pharmacies can persuade patients with a brand-name prescription to purchase a generic version instead. We show that pharmacies’ substitution incentives are determined by relative margins and relative patient copayments. Second, we exploit a unique product level panel data set, which contains information on sales and prices at both producer and retail level. In the empirical analysis, we find a strong relationship between the margins of brand-names and generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than coinsurance. In term...
In recent years health insurers have placed a great deal of emphasis on the ability of generic medic...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmac...
Background: As in other societies, pharmaceutical expenditures in the Netherlands are rising every y...
We study the impact of product margins on pharmacies’ incentive to promote generics instead of brand...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharma...
This paper examines the price effects of generic drugs that are produced by brand-name drug firms an...
Earlier studies have pointed at the presence of a generics paradox in the US prescription drug marke...
Empirical studies suggest that entry of generic competitors results in minimal decreases or even inc...
In this paper we study the effect of reference pricing on pharmaceutical prices and expenditures whe...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmac...
Generic drugs comprise an increasing share of total prescriptions dispensed in the U.S., rising from...
We study the effect of the degree of exclusivity for the lowest bidder on the averageprice of generi...
Patients would normally be expected to view a brand and generic drug pair, once certified as being c...
We study the impact of regulation on competition between brand-names and generics and pharmaceutical...
The issue of high drug prices has recently exploded into public consciousness. And while many potent...
In recent years health insurers have placed a great deal of emphasis on the ability of generic medic...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmac...
Background: As in other societies, pharmaceutical expenditures in the Netherlands are rising every y...
We study the impact of product margins on pharmacies’ incentive to promote generics instead of brand...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharma...
This paper examines the price effects of generic drugs that are produced by brand-name drug firms an...
Earlier studies have pointed at the presence of a generics paradox in the US prescription drug marke...
Empirical studies suggest that entry of generic competitors results in minimal decreases or even inc...
In this paper we study the effect of reference pricing on pharmaceutical prices and expenditures whe...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmac...
Generic drugs comprise an increasing share of total prescriptions dispensed in the U.S., rising from...
We study the effect of the degree of exclusivity for the lowest bidder on the averageprice of generi...
Patients would normally be expected to view a brand and generic drug pair, once certified as being c...
We study the impact of regulation on competition between brand-names and generics and pharmaceutical...
The issue of high drug prices has recently exploded into public consciousness. And while many potent...
In recent years health insurers have placed a great deal of emphasis on the ability of generic medic...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmac...
Background: As in other societies, pharmaceutical expenditures in the Netherlands are rising every y...